Cargando…
Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct
Regulatory T cells, Tregs, are a subset of lymphocytes that have immunosuppressive attributes. They are elevated in blood of glioblastoma patients and within this tumor's tissue itself. Indoleamine 2,3-dioxygenase, IDO, converts tryptophan to kynurenine. IDO activity enhances Treg formation by...
Autores principales: | Söderlund, Johan, Erhardt, Sophie, Kast, Richard E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925358/ https://www.ncbi.nlm.nih.gov/pubmed/20691089 http://dx.doi.org/10.1186/1742-2094-7-44 |
Ejemplares similares
-
“High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers
por: Elkoshi, Zeev
Publicado: (2020) -
How to detour Treg cells in T cell-based antitumor immune therapy
por: Zheng, Shu, et al.
Publicado: (2013) -
Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers
por: Kast, Richard E.
Publicado: (2015) -
IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity
por: Lippens, Carla, et al.
Publicado: (2016) -
Inhibiting the NLRP3 Inflammasome With Methylene Blue as Treatment Adjunct in Myelodysplasia
por: Kast, Richard E.
Publicado: (2018)